NanoPass's intradermal injection platform proven to sustain COVID-19 vaccine antibodies using 1/15 of the dose reports Chinese Institute of Medical Biology
Nes Ziona, Israel and Shanghai, China (ots/PRNewswire) - Intradermal COVID vaccination studies are emerging in a global effort to multiply available doses by harnessing skin immunity to reduce dosage required for effective vaccination. In a hallmark study published recently by IMB scientists[1], subjects were ...
mehr